Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions
CS Walmsley, Z Schoepflin, C De Brabandt… - Blood Cells, Molecules …, 2024 - Elsevier
Hemophagocytic lymphohistiocytosis (HLH) is a severe and often lethal inflammatory
syndrome characterized by excessive immune activation leading to fever, cytopenias, and …
syndrome characterized by excessive immune activation leading to fever, cytopenias, and …
[HTML][HTML] Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature
LL Liu, M Skribek, U Harmenberg… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint
inhibitors: case report and systematic review of the literature - PMC Back to Top Skip to …
inhibitors: case report and systematic review of the literature - PMC Back to Top Skip to …
Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review
Background Programmed cell death protein 1 (PD-1) checkpoint inhibitors such as
pembrolizumab are novel therapeutics used to treat various advanced malignancies …
pembrolizumab are novel therapeutics used to treat various advanced malignancies …
Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent …
I Dirven, AS Vander Mijnsbrugge, S Mignon… - Melanoma …, 2023 - journals.lww.com
Auto-immune hemolytic anemia (AIHA) and hemophagocytic lymphohistiocytosis (HLH) are
both rare immune-related adverse events (irAEs) following treatment with immune …
both rare immune-related adverse events (irAEs) following treatment with immune …
Early effects of nivolumab and ipilimumab combined immunotherapy in the treatment of metastatic melanoma in Poland: a multicenter experience
R Pacholczak-Madej, A Grela-Wojewoda… - Biomedicines, 2022 - mdpi.com
Nivolumab and ipilimumab combination became the first-line standard in advanced
melanoma. We assessed its efficacy in a real-life study in Poland. In a one-year follow-up …
melanoma. We assessed its efficacy in a real-life study in Poland. In a one-year follow-up …
Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases
Z Xu, H Li, X Yu, J Luo, Z Zhang - Hematology, 2024 - Taylor & Francis
Objective: An association exists between immune checkpoint inhibitors and hemophagocytic
lymphohistiocytosis (HLH). Therefore, the main objective of this study was to collect data on …
lymphohistiocytosis (HLH). Therefore, the main objective of this study was to collect data on …
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: Systematic review of the literature
LL Liu, M Skribek, U Harmenberg, M Gerling - medRxiv, 2022 - medrxiv.org
Immune checkpoint inhibitors (ICIs) are associated with a wide range of immune-related
adverse events (irAEs). As oncological indications for ICIs widen, their rare side effects …
adverse events (irAEs). As oncological indications for ICIs widen, their rare side effects …
[PDF][PDF] Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and …
B Neyns - biblio.vub.ac.be
Auto-immune hemolytic anemia (AIHA) and hemophagocytic lymphohistiocytosis (HLH) are
both rare immune related adverse events (irAE) following treatment with immune checkpoint …
both rare immune related adverse events (irAE) following treatment with immune checkpoint …